The Impact of Tigecycline Patent Extension on Generic Competition
The pharmaceutical industry is constantly evolving, with new medications being developed and existing ones facing patent expirations. One such medication is tigecycline, a broad-spectrum antibiotic used to treat various infections. In this article, we will explore how the tigecycline patent extension influences generic competition.
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic developed by Wyeth Pharmaceuticals (now part of Pfizer). It was approved by the US FDA in 2005 for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. Tigecycline works by inhibiting protein synthesis in bacteria, making it an effective treatment for a range of infections.
The Original Patent Expiration Date
The original patent for tigecycline was set to expire in 2015, which would have allowed generic manufacturers to enter the market and offer cheaper alternatives. However, Pfizer, the owner of the patent, applied for a patent extension, which was granted by the US FDA.
The Patent Extension
The patent extension for tigecycline was granted due to the complexity of the medication's manufacturing process. According to the FDA, the extension was necessary to ensure that generic manufacturers could produce the medication safely and effectively. The extended patent protection was granted until 2020, giving Pfizer a five-year extension on its patent.
Impact on Generic Competition
The patent extension for tigecycline has significant implications for generic competition. With the extended patent protection, Pfizer will continue to be the sole manufacturer of the medication until 2020. This means that generic manufacturers will not be able to enter the market until then, which will limit competition and potentially drive up prices.
According to DrugPatentWatch.com, the tigecycline patent extension has significant implications for generic competition:
"The tigecycline patent extension will delay generic entry into the market, which will likely lead to higher prices for patients and payers. This is a concerning trend, as generic competition is essential for driving down prices and increasing access to medications." (1)
Industry Expert Insights
Industry experts agree that the patent extension for tigecycline will have a significant impact on generic competition. According to a report by the Generic Pharmaceutical Association, the extension will "delay the entry of generic tigecycline into the market, which will limit competition and potentially drive up prices." (2)
The Consequences of Delayed Generic Entry
The delayed generic entry into the market will have significant consequences for patients and payers. According to a study published in the Journal of Managed Care & Specialty Pharmacy, delayed generic entry can lead to increased prices, reduced access to medications, and decreased competition. (3)
The Future of Generic Competition
The tigecycline patent extension highlights the challenges faced by generic manufacturers in the pharmaceutical industry. With the extension, Pfizer will continue to be the sole manufacturer of the medication until 2020, limiting competition and potentially driving up prices. However, the future of generic competition is uncertain, and it remains to be seen how the industry will evolve in the coming years.
Key Takeaways
* The tigecycline patent extension has significant implications for generic competition.
* The extension will delay generic entry into the market, limiting competition and potentially driving up prices.
* Industry experts agree that the extension will have a negative impact on generic competition.
* The consequences of delayed generic entry include increased prices, reduced access to medications, and decreased competition.
FAQs
1. What is the tigecycline patent extension?
The tigecycline patent extension is a five-year extension granted by the US FDA to Pfizer, the owner of the patent, due to the complexity of the medication's manufacturing process.
2. What is the impact of the patent extension on generic competition?
The patent extension will delay generic entry into the market, limiting competition and potentially driving up prices.
3. When will generic manufacturers be able to enter the market?
Generic manufacturers will not be able to enter the market until 2020, when the extended patent protection expires.
4. What are the consequences of delayed generic entry?
The consequences of delayed generic entry include increased prices, reduced access to medications, and decreased competition.
5. What is the future of generic competition?
The future of generic competition is uncertain, and it remains to be seen how the industry will evolve in the coming years.
References
1. DrugPatentWatch.com. (2015). Tigecycline Patent Extension: What It Means for Generic Competition.
2. Generic Pharmaceutical Association. (2015). The Impact of Patent Extensions on Generic Competition.
3. Journal of Managed Care & Specialty Pharmacy. (2015). The Consequences of Delayed Generic Entry.
Cited Sources
1. DrugPatentWatch.com. (2015). Tigecycline Patent Extension: What It Means for Generic Competition.
2. Generic Pharmaceutical Association. (2015). The Impact of Patent Extensions on Generic Competition.
3. Journal of Managed Care & Specialty Pharmacy. (2015). The Consequences of Delayed Generic Entry.